NASDAQ / LIVE COMPANY INTELLIGENCE

Regeneron Pharmaceuticals, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERREGN
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / REGN COVERAGE

What’s moving Regeneron Pharmaceuticals, Inc. now

Current reporting with the operating signal separated from the noise.

01
Regeneron Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary

Regeneron Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary

Investors are testing whether Regeneron Pharmaceuticals, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
02
Regeneron Pharmaceuticals, Inc.: Regeneron Reports Second Quarter 2026 Financial and Operating Results

Regeneron Pharmaceuticals, Inc.: Regeneron Reports Second Quarter 2026 Financial and Operating Results

The story matters when it changes Regeneron Pharmaceuticals, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
2nd Annual Healthcare Forum Transcript

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Bernstein Insights: Healthcare Leaders and Disruptors

The story matters when it changes Regeneron Pharmaceuticals, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
04
Did You Lose Money Investing in Regeneron Pharmaceuticals, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights ...

Did You Lose Money Investing in Regeneron Pharmaceuticals, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights ...

The story matters when it changes Regeneron Pharmaceuticals, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
05
Regeneron Pharmaceuticals, Inc. v. Amgen Inc.: Jury Finds Rebate Offers on Bundled Drugs in Exchange for Exclusive Formulary Placement Violate Antitrust Laws

Regeneron Pharmaceuticals, Inc. v. Amgen Inc.: Jury Finds Rebate Offers on Bundled Drugs in Exchange for Exclusive Formulary Placement Violate Antitrust Laws

The decision can change Regeneron Pharmaceuticals, Inc.’s market access, costs and competitive freedom.

Watch next: confirmation in a company filing, official release or regulator record.
PRIMARY DOCUMENTS / SEC EDGAR

Latest REGN filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-07-30 · Period 2026-06-30SEC ↗10-QQuarterly financial reportFiled 2026-04-29 · Period 2026-03-31SEC ↗10-KAnnual financial reportFiled 2026-02-04 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-07-30 · Period 2026-07-30SEC ↗8-KMaterial company eventFiled 2026-07-06 · Period 2026-07-06SEC ↗8-KMaterial company eventFiled 2026-06-17 · Period 2026-06-12SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-24 · Period 2026-06-12SEC ↗4Official SEC filingFiled 2026-07-07 · Period 2026-07-02SEC ↗
EARNINGS / QUARTERLY TRACKER

Regeneron Pharmaceuticals, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.